Evidence map›Paper›PMID 30251110›Full record

ArticleHigh blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension2018

Lowering Blood Pressure with the Combination of a Sodium-Glucose Cotransporter 2 Inhibitor and a Glucagon-like Peptide-1 Receptor Agonist in Type 2 Diabetic Patients: A Clinical Evidence.

José Carlos Arévalo-Lorido, Juana Carretero Gómez, Ricardo Gómez Huelgas, Dolores García de Lucas, Lourdes Mateos Polo, José Manuel Varela Aguilar, Javier Ena Muñoz

Abstract read
PubMed Publisher
In one paragraph

Article in High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

José Carlos Arévalo-LoridoInternal Medicine Department, Zafra County Hospital, Ctra Badajoz-Granada s/n, 06300, Zafra, Badajoz, Spain. joscarlor@gmail.com.ORCID http://orcid.org/0000-0002-2654-9339
Juana Carretero GómezInternal Medicine Department, Zafra County Hospital, Ctra Badajoz-Granada s/n, 06300, Zafra, Badajoz, Spain.
Ricardo Gómez HuelgasInternal Medicine Department, University Hospital of Málaga, Avda de Carlos Haya, s/n, 29010, Málaga, Spain.
Dolores García de LucasInternal Medicine Department, "Costa del sol" Hospital, Autovía A7, Km 187, 29603, Marbella, Málaga, Spain.
Lourdes Mateos PoloInternal Medicine Department, University Hospital of Salamanca, Paseo de San Vicente 182, 37007, Salamanca, Spain.
José Manuel Varela AguilarInternal Medicine Department, University Hospital "Virgen del Rocio", Av. Manuel Siurot, s/n, 41013, Sevilla, Spain.
Javier Ena MuñozInternal Medicine Department, "Marina Baixa" Hospital, Avda, Alcalde En Jaume Botella Mayor, s/n, 03570, La Vila Joiosa, Alicante, Spain.
Centro de Implantología Cirugía Oral y Maxilofacial · ESHospital Costa del Sol · ESHospital Marina Baixa · ESHospital Universitario Virgen del Rocío · ESUniversidad de Málaga · ESUniversidad de Salamanca · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with type 2 diabetes mellitus (T2DM) often have numerous cardiovascular risk factors, among which hypertension.

aimTo evaluate the blood pressure variations among patients treated with a combination of a sodium-glucose cotransporter 2 inhibitor (iSGLT-2) and a glucagon-like peptide-1 receptor agonist (GLP-1ra).

methodsWe analyze 17 patients treated with this combination to quantify the changes on blood pressure by ambulatory blood pressure monitoring at baseline and at three and 6 months follow-up.

resultsWe observed a decrease of HbA1c levels (p = 0.004) at six months follow-up, a decrease in mean 24 h systolic blood pressure [from 124 (11) mmHg to 123 (4.75) mmHg, p = 0.04] and in both, mean waking and sleeping systolic blood pressure, being greater the reduction in the sleeping time [118 (20) mmHg to 111 (20) mmHg, p = 0.004].

conclusionThe effect of a combination therapy of an iSGLT-2 and a GLP-1ra on blood pressure in a real-world setting, may have summative effects especially in SBP.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsAgedBiomarkersBlood GlucoseBlood PressureDiabetes Mellitus, Type 2Drug Therapy, CombinationFemaleGlucagon-Like Peptide-1 ReceptorGlycated HemoglobinHumansIncretinsMaleMiddle AgedSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsBiomarkersBlood GlucoseGLP1R protein, humanGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsGlycated Hemoglobinhemoglobin A1c protein, humanIncretinsSLC5A2 protein, humanSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsAmbulatory blood pressure monitoringDiabetesGlucagon-like peptide-1 receptor agonistSodium-glucose cotransporter 2 inhibitor

Identifiers

PMID30251110
OpenAlexW2894194852

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.